In other mid-week developments, House Energy and Commerce Committee chairman Rep. Henry Waxman introduced a bipartisan bill to create a regulatory pathway for generic versions of expensive biotech prescription drugs. There appears to be a fly in the ointment according to this AP report,
The debate over an approval process for biotech copies has dragged on for years, with both the biotechnology and generic drug industries at loggerheads over how much competition-free marketing the original drugs should get. The biotechnology industry has called for up to 14 years of exclusivity for their drugs before a copy could be introduced.
But the bill instead mirrors the current system for chemical compounds, which allows for five years of market exclusivity for new drugs and up to three years additional exclusivity for modifications.